Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' dTpa Booster Vaccine (263855) (Boostrix) Administered as a Booster Dose in Healthy Russian Subjects

NCT03311659 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03311659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03311659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' dTpa Booster Vaccine (263855) (Boostrix) Administered as a Booster Dose in Healthy Russian Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
January 26, 2018
Completion date
August 31, 2018
Enrollment
448 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria-tetanus-acellular pertussis vaccines